Coagulation Disorder, Covid19, Pneumonia, Pulmonary Embolism
Conditions
Keywords
Covid-19, Mortality, anticoagulants, Deep venous thrombosis, Pulmonary embolism
Brief summary
Viral infections provoke the systemic inflammatory response and cause an imbalance between the procoagulant and anticoagulant homeostatic mechanisms. Multiple pathogenic mechanisms are involved, including endothelial dysfunction, increased von Willebrand factor, Toll receptor activation, and tissue factor pathway activation. D-dimer levels greater than 1000 ng / mL are associated with an 18-fold increased risk of mortality. In this context, many patients may require prophylaxis or antithrombotic treatment with low molecular weight heparins. Currently, there is no validated scheme on the dose and timing of the use of antithrombotic drugs. The study aims to identify the effect of two anticoagulant strategies (prophylactic and therapeutic) on the progression to ventilatory support or death in patients with COVID-19 infection who require hospital care.
Detailed description
Randomized clinical trial in patients with a confirmed infection by COVID-19 who require hospital treatment and subsequent ambulatory surveillance. Study population. Patients with a diagnosis by PCR of COVID 19, over 18 years of age from the High Specialty Hospital of Ixtapaluca, who meet the inclusion criteria. Statistic analysis. The student's T-test was carried out to identify the difference in the means of the quantitative variables between the groups. A value of P ≤ 0.05, 95% CI will be considered significant. For the hypothesis test, the chi-square test will be performed, considering a p≤ 0.05, 95% CI value to be significant.
Interventions
DRUGEnoxaparin
Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the established clinical response due to lack of ventilatory support, length of hospital stay or death in patients requiring hospital care for COVID-19 infection.
Sponsors
Hospital Regional de Alta especialidad de Ixtapaluca
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)
Intervention model description
* Initially they will be randomized into two blocks, the first based on prophylactic Enoxaparin (Numbers 1 to 64) and the second (Numbers 65 to 128) will be assigned to the Enoxaparin therapeutic regimen arm at doses of 1mg / kg/dose twice up to date * During hospitalization, the clinical evolution will be evaluated according to the requirements of mechanical ventilation, the reduction in D-Dimer levels and the clinical outcome (discharge or death). * Those patients who are discharged will be Randomized in two following treatment arms * The allocation of patients in the outpatient stage will be carried out randomly 1: 1 to receive Rivaroxaban 10mg PO every 24hrs or only clinical follow-up. * Follow-up of adverse events will be carried out in the Hematology outpatient clinic with a first consultation 15 days after discharge and a second consultation 30 days after discharge. With dimer D, ferritin, protein C, blood count, ESR and on day 30 with CAT.
Eligibility
Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of COVID-19 infection confirmed by polymerase chain reaction test (RQ-PCR) requiring hospital care for the administration of supplemental oxygen
Exclusion criteria
* Patients with life expectancy less than 48hrs * Patients who require ventilatory support upon admission * Age over 75 years or with a history of atrial fibrillation * History of venous or arterial thrombosis * Severe neurological impairment * Absence of a primary caregiver to supervise the administration of medication * History of cerebral hemorrhage * History of previous use of oral anticoagulants * History of major surgery 30 days prior to admission * Uncontrolled systemic arterial hypertension * KDIGO stage III chronic kidney disease or less * Hemodialysis or peritoneal dialysis treatment * History of active or inactive cancer * Pregnant or postpartum patients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| low molecular weight heparin (enoxaparin) and ventilatory support time | 30 days | Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on ventilatory support time in patients requiring hospital care for COVID-19 infection. |
| thrombotic complications and Rivaroxaban | 30 days | To compare oral anticoagulation therapy by administering Rivaroxaban 10mg PO every 24 hours on early thrombotic complications |
| low molecular weight heparin (enoxaparin) and length of hospital stay | 30 days | Identify the benefit of different doses of low molecular weight heparin (enoxaparin) on the length of hospital stay in patients requiring hospital care for COVID-19 infection. |
| low molecular weight heparin (enoxaparin) and mortality rate | 30 days | Identify the benefit of different doses of low molecular weight heparin (enoxaparin) over mortality rate in patients requiring hospital care for COVID-19 infection. |
Countries
Mexico
Contacts
Primary ContactOmar Ramos-Peñafiel, MD, PhD
Outcome results
None listed